Insider Selling: Kenneth Traverso Sells 4,225 Shares of Natus Medical Stock (BABY)
Natus Medical (NASDAQ:BABY) VP Kenneth Traverso sold 4,225 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $13.89, for a total value of $58,685.25. Following the sale, the vice president now directly owns 104,029 shares in the company. The sale was disclosed in a legal filing with the SEC, which is available at this link.
A number of analysts have recently weighed in on BABY shares. Analysts at Zacks downgraded shares of Natus Medical (NASDAQ:BABY) from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, July 10th. They now have a $12.40 price target on the stock. Separately, analysts at Roth Capital cut their price target on shares of Natus Medical (NASDAQ:BABY) from $17.00 to $15.00 in a research note to investors on Tuesday, July 9th. They now have a “buy” rating on the stock. Finally, analysts at Raymond James cut their price target on shares of Natus Medical (NASDAQ:BABY) from $17.00 to $15.00 in a research note to investors on Tuesday, July 9th. They now have an “outperform” rating on the stock.
Natus Medical (NASDAQ:BABY) traded down 3.22% on Thursday, hitting $13.53. 128,053 shares of the company’s stock traded hands. Natus Medical has a 52-week low of $9.65 and a 52-week high of $15.18. The stock has a 50-day moving average of $13.43 and a 200-day moving average of $13.40. The company has a market cap of $405.3 million and a P/E ratio of 39.94.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.21 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.14 by $0.07. The company had revenue of $82.30 million for the quarter, compared to the consensus estimate of $83.50 million. During the same quarter last year, the company posted $0.12 earnings per share. Natus Medical’s revenue was up 34.9% compared to the same quarter last year. Analysts expect that Natus Medical will post $0.79 EPS for the current fiscal year.
Natus Medical Incorporated (NASDAQ:BABY) is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.